ABSTRACT
Background The global COVID-19 pandemic has the potential to indirectly impact the transmission dynamics and prevention of HIV and other sexually transmitted infections (STI). Studies have already documented reductions in sexual activity (“sexual distancing”) and interruptions in HIV/STI services, but it is unknown what combined impact these two forces will have on HIV/STI epidemic trajectories.
Methods We adapted a network-based model of co-circulating HIV, gonorrhea, and chlamydia for a population of approximately 103,000 men who have sex with men (MSM) in the Atlanta area. Model scenarios varied the timing, overlap, and relative extent of COVID-related sexual distancing in casual and one-time partnership networks and service interruption within four service categories (HIV screening, HIV PrEP, HIV ART, and STI treatment).
Results A 50% relative decrease in sexual partnerships and interruption of all clinical services, both lasting 18 months, would generally offset each other for HIV (total 5-year population impact for Atlanta MSM: −227 cases), but have net protective effect for STIs (−23,800 cases). Greater relative reductions and longer durations of service interruption would increase HIV and STI incidence, while greater relative reductions and longer durations of sexual distancing would decrease incidence of both. If distancing lasted only 3 months but service interruption lasted 18 months, the total 5-year population impact would be an additional 890 HIV cases and 57,500 STI cases.
Conclusions The counterbalancing impact of sexual distancing and clinical service interruption depends on the infection and the extent and durability of these COVID-related changes. If sexual behavior rebounds while service interruption persists, we project an excess of hundreds of HIV cases and thousands of STI cases just among Atlanta MSM over the next 5 years. Immediate action to limit the impact of service interruptions is needed to address the indirect effects of the global COVID pandemic on the HIV/STI epidemic.
Competing Interest Statement
JLM has previously consulted for Kaiser Permanente Northern California on a research grant from Gilead Sciences. DW has consulted for Sanofi-Pasteur on unrelated topics.
Funding Statement
This work was supported by grants from National Institutes of Health grant (R01 AI138783 and P30AI050409) and the MAC AIDS Fund. JLM is supported in part by the National Institute of Allergy and Infectious Diseases (grant K01 AI122853).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Emory University Institutional Review Board approved the human subjects research component of the ARTnet and AMIS studies that generated primary data for use in this model.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
FUNDING This work was supported by grants from National Institutes of Health grant (R01 AI138783 and P30 AI050409) and the MAC AIDS Fund. JLM is supported in part by the National Institute of Allergy and Infectious Diseases (grant K01 AI122853).
DISCLOSURES JLM has previously consulted for Kaiser Permanente Northern California on a research grant from Gilead Sciences. DW has consulted for Sanofi-Pasteur on unrelated topics.
Edited text throughout for clarity. Fixed plotting of temporal outcomes in Figures 1 and 3.
Data Availability
Model code and data are available at the Github repositories linked in the Supplemental Appendix document.
